Investigational drug · Phase 2
HS-10365
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nonsmall Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HS-10365"
First trial start
2023
Sep 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10365", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nonsmall Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10365" as an intervention, largest first.
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05207787 · 306 participants (planned) · Start Nov 9, 2021 · Primary completion Apr 30, 2024
Drug: HS-10365 · For: Solid Tumor
Sites: Shanghai, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06147570 · 62 participants (planned) · Start Sep 25, 2023 · Primary completion Aug 31, 2027
Drug: HS-10365 capsules · For: Nonsmall Cell Lung Cancer
Sites: Shanghai, China
- Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic FunctionNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06823258 · 32 participants (planned) · Start Feb 28, 2025 · Primary completion Jul 31, 2025
Drug: HS-10365 · For: NSCLC (advanced Non-small Cell Lung Cancer)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Nonsmall Cell Lung Cancer
- 1.0% IP-001IP-001Phase 32 trials
Immunophotonics, Inc. · Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer
- VMD-102Single agentPhase 21 trial
VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)
- XP-102Phase 21 trial
Xynomic Pharmaceuticals, Inc. · Cancer, BRAF V600 Mutation, Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.